Comprehensive Accounts of Pharmaceutical Research and Development

Ahmed F. Abdel-Magid received his Bachelor's degree (1969) and Master's degree (1973) from Cairo University and his PhD (1980) from Temple University. After postdoctoral appointments at the University of South Carolina and SmithKline Beckman Pharmaceuticals, he worked at Drexel University as Teaching/Research Associate (1985-1986) then as Adjunct Professor (1986-2006). He joined the Process Chemistry Department at Wyeth Laboratories as Senior Chemist (1986-1987), then moved to the Process Chemistry Group at Johnson & Johnson PRD (1987-2008) as a Senior Scientist and rose through the ranks to Senior Research Fellow. He joined Therachem Research Medilab in 2009 where he holds the title of Executive VP and Chief Scientific Officer. Jaan A. Pesti received his BS degree from Long Island University, Brooklyn, NY in 1976 and his Ph.D. in organic chemistry from Columbia University in 1981. Following postdoctoral research in synthetic organic chemistry at University of California, Berkeley from 1981-1983, he joined the staff of Dupont's Medical Products Division in Wilmington, DE and Deepwater, NJ. He later transitioned to Dupont Merck Pharmaceuticals, Dupont Pharmaceuticals, and joined Bristol-Myers Squibb Pharmaceuticals in 2001. He retired from BMS in 2013 after 30 years of service, but has worked for NAL Pharma, Gelest Inc., and EnginZyme AB since that date. Rajappa Vaidyanathan obtained his Bachelor's degree from Loyola College, Madras, and his Master's from the Indian Institute of Technology, Madras. He completed his Ph.D. in 1998 from the University of California, Irvine. After a post-doctoral appointment at Eli Lilly and Company, he joined the Chemical Process R&D group of Pharmacia Corporation, Kalamazoo, MI, and subsequently Pfizer in Groton, CT. He is currently Group Director and Head of Chemical, Synthetic and Analytical Development at Bristol-Myers Squibb in Bangalore, India.

Preface
1. Synthesis of a Potent NAE Inhibitor: Pevonedistat
2. Process Development and GMP Production of a Potent NEDD8-Activating Enzyme (NAE) Inhibitor: Pevonedistat
3. The Discovery and Synthesis of the CGRP Receptor Antagonist MK-3207
4. Design and Enabling Development of Hydroxyethylamine-Derived BACE1 Inhibitor
5. Identification and Optimization of a Series of Non-Steroidal Trifluoromethylcarbinol Glucocorticoid Receptor Agonists
6. Development of an Asymmetric Route for Large-Scale Synthesis of a Glucocorticoid Agonist
7. The Medicinal Chemistry and Commercial Manufacturing Behind the Discovery and Development of the Hedgehog Inhibitor Vismodegib
8. Discovery and Process Development of Class I PI3K and Class I PI3K/mTOR Inhibitors GDC-0941 and GDC-0980
9. The Development and Manufacture of Azacitidine, Decitabine, and Cladribine: Stereoselective Ribonucleoside Drug Synthesis Using the Vorbrüggen Glycosylation
Editors' Biographies
Indexes